NUVAIRA Revenue and Competitors
Estimated Revenue & Valuation
- NUVAIRA's estimated annual revenue is currently $7M per year.
- NUVAIRA's estimated revenue per employee is $125,500
- NUVAIRA's total funding is $188.9M.
Employee Data
- NUVAIRA has 56 Employees.
- NUVAIRA grew their employee count by -21% last year.
NUVAIRA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $30.6M | 122 | 4% | N/A | N/A |
#2 | $18.6M | 74 | 35% | N/A | N/A |
#3 | $75.6M | 301 | 20% | N/A | N/A |
#4 | $12M | 48 | 4% | N/A | N/A |
#5 | $2.8M | 11 | 10% | N/A | N/A |
#6 | $3M | 12 | 0% | N/A | N/A |
#7 | $24.6M | 98 | 5% | N/A | N/A |
#8 | $11.5M | 46 | 21% | N/A | N/A |
#9 | $7.3M | 29 | 4% | N/A | N/A |
#10 | $13.8M | 55 | -10% | N/A | N/A |
What Is NUVAIRA?
Nuvaira, Inc., is a privately held medical device company that develops minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases. Specifically, the company is developing a novel, catheter-based system to address chronic obstructive pulmonary disease, or COPD, by treating the overactive airway nerves in a procedure call Targeted Lung Denervation* (TLD). *Targeted Lung Denervation (TLD) is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available. Nuvaira and dNerva are trademarks of Nuvaira, Inc.
keywords:N/A
$188.9M
Total Funding
56
Number of Employees
$7M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NUVAIRA's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Human Resources Director | Reveal Email/Phone |
2 | Director, Supply Chain and Manufacturing | Reveal Email/Phone |
3 | Senior Accountant | Reveal Email/Phone |
4 | Marketing Operations Manager | Reveal Email/Phone |
5 | Director Market Development | Reveal Email/Phone |
6 | Director Quality | Reveal Email/Phone |
7 | VP Science, Clinical, and R&D | Reveal Email/Phone |
8 | Sr. Clinical Data Specialist | Reveal Email/Phone |
9 | Director Research and Development | Reveal Email/Phone |
10 | Principal Quality Engineer | Reveal Email/Phone |
NUVAIRA News
300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy. MINNEAPOLIS, Jan. 25, 2022 /PRNewswire/ -- Nuvaira,...
MINNEAPOLIS, Aug. 11, 2021 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that 100 patients have been randomized in the FDA pivotal AIRFLOW-3 Clinical Trial. This COPD trial is evaluating the safety and effectiveness of th ...
MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded trial (AIRFLOW-2) that confirms long-term safety and d ...
Nuvaira, a Minneapolis, Minnesota-based developer of novel therapeutic medical devices for treating obstructive lung diseases, has raised $79 million in funding led by U.S. Venture Partners. Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation also jo ...
Other Companies in Minneapolis
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.6M | 56 | -12% | N/A |
#2 | $6.8M | 56 | -25% | $4.1M |
#3 | $12.7M | 56 | -10% | N/A |
#4 | $7.1M | 56 | 27% | N/A |
#5 | $13.6M | 56 | 8% | N/A |